Semmax Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Semmax Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$6.15K	Hold	14	–	–	﹤0.01%	286
2025 Q1	$3.52K	Hold	14	–	–	﹤0.01%	298
2024 Q4	$3.71K	Hold	14	–	–	﹤0.01%	270
2024 Q3	$3.77K	Hold	14	–	–	﹤0.01%	265
2024 Q2	$3.75K	Hold	14	–	–	﹤0.01%	298
2024 Q1	$2.1K	Hold	14	–	–	﹤0.01%	301
2023 Q4	$2.27K	Hold	14	–	–	﹤0.01%	306
2023 Q3	$2.31K	Buy	+14	New	+$2.67K	﹤0.01%	269
2022 Q4	$3K	Hold	14	–	–	﹤0.01%	218
2022 Q3	$3K	Sell	14 -807	-98%	-$154K	﹤0.01%	208
2022 Q2	$190K	Sell	821 -100	-11%	-$14.2K	0.08%	91
2022 Q1	$150K	Sell	921 -72	-7%	-$11K	0.06%	107
2021 Q4	$168K	Sell	993 -189	-16%	-$35.1K	0.06%	108
2021 Q3	$223K	Sell	1,182 -138	-10%	-$25.9K	0.08%	102
2021 Q2	$224K	Buy	1,320 +19	+1%	+$2.78K	0.07%	104
2021 Q1	$184K	Buy	+1,301	New	+$196K	0.07%	103

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Semmax Financial Advisors's ALNY Position: Q2 2025 in Review

Semmax Financial Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2025 at 14 shares worth $6.15K. The position accounts for ﹤0.01% of the portfolio, ranked #286.

Semmax Financial Advisors first reported a position in ALNY in Q1 2021 and has held it in 16 quarters since. The position peaked at $224K in Q2 2021. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

Semmax Financial Advisors held 14 shares of Alnylam Pharmaceuticals worth $6.15K as of Q2 2025.
Semmax Financial Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2025.
Alnylam Pharmaceuticals made up ﹤0.01% of Semmax Financial Advisors's portfolio in Q2 2025, its #286 holding.
Semmax Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
Semmax Financial Advisors's Alnylam Pharmaceuticals position peaked at $224K in Q2 2021.
654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Semmax Financial Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.